| NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 31722-0782-30 | 31722-0782 | Afatinib | Afatinib | 30.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR, HER2, HER4 | Oral | Jul 14, 2026 | In Use | |
| 31722-0781-30 | 31722-0781 | Afatinib | Afatinib | 20.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR, HER2, HER4 | Oral | Jul 14, 2026 | In Use | |
| 84577-0751-01 | 84577-0751 | Gedatolisib | REVTORPYK | 180.0 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR, PI3K (⍺,β,ƍ,γ) | Intravenous | Jul 14, 2026 | In Use | |
| 69448-0008-03 | 69448-0008 | Filgrastim-laha | FILKRI | 300.0 ug/.5mL | Ancillary Therapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | Intravenous, Subcutaneous | Jul 15, 2026 | In Use | |
| 69448-0009-63 | 69448-0009 | Filgrastim-laha | FILKRI | 480.0 ug/.8mL | Ancillary Therapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | Intravenous, Subcutaneous | Jul 15, 2026 | In Use | |
| 69448-0009-03 | 69448-0009 | Filgrastim-laha | FILKRI | 480.0 ug/.8mL | Ancillary Therapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | Intravenous, Subcutaneous | Jul 15, 2026 | In Use | |
| 68001-0708-25 | 68001-0708 | Palonosetron Hydrochloride | Palonosetron | 0.25 mg/5mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intravenous | Jul 15, 2026 | In Use | |
| 83831-0164-10 | 83831-0164 | Fluorouracil | FAVLYXA | 25.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | Jul 15, 2026 | In Use | |
| 68071-3738-03 | 68071-3738 | PREDNISONE | PREDNISONE | 20.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Jul 21, 2026 | In Use | |
| 85001-0102-01 | 85001-0102 | Zidesamtinib | JIDEYTRO | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | ROS1, ALK, TRK | Oral | Jul 22, 2026 | In Use | |
| 85001-0101-01 | 85001-0101 | Zidesamtinib | JIDEYTRO | 25.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | ROS1, ALK, TRK | Oral | Jul 22, 2026 | In Use | |
| 83831-0153-01 | 83831-0153 | Fosaprepitant | NAVITRUX | 150.0 mg/5mL | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Intravenous | Jul 23, 2026 | In Use | |
| 52817-0860-08 | 52817-0860 | Prednisolone oral | Prednisolone | 15.0 mg/5mL | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Aug 4, 2026 | In Use | |
| 52817-0860-16 | 52817-0860 | Prednisolone oral | Prednisolone | 15.0 mg/5mL | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Aug 4, 2026 | In Use | |
| 76282-0768-09 | 76282-0768 | Paclitaxel protein-bound particles | Paclitaxel 100mg per vial | 100.0 mg/20mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Aug 11, 2026 | In Use | |
| 43598-0888-30 | 43598-0888 | Prednisone | Prednisone delayed release | 5.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Aug 12, 2026 | In Use | |
| 43598-0888-01 | 43598-0888 | Prednisone | Prednisone delayed release | 5.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Aug 12, 2026 | In Use | |
| 00003-5710-21 | 00003-5710 | Iberdomide | ZENBEXUS | 1.0 mg/1 | Chemotherapy | Protein Degrader | Cereblon | Oral | Aug 13, 2026 | In Use | |
| 00003-5700-21 | 00003-5700 | Iberdomide | ZENBEXUS | 0.75 mg/1 | Chemotherapy | Protein Degrader | Cereblon | Oral | Aug 13, 2026 | In Use | |
| 83980-0018-10 | 83980-0018 | Ondansetron hydrochloride | Ondansetron hydrochloride | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Aug 14, 2026 | In Use | |
| 83980-0017-10 | 83980-0017 | Ondansetron hydrochloride | Ondansetron hydrochloride | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Aug 14, 2026 | In Use | |
| 83980-0018-13 | 83980-0018 | Ondansetron hydrochloride | Ondansetron hydrochloride | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Aug 14, 2026 | In Use | |
| 83980-0017-97 | 83980-0017 | Ondansetron hydrochloride | Ondansetron hydrochloride | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Aug 14, 2026 | In Use | |
| 83980-0017-13 | 83980-0017 | Ondansetron hydrochloride | Ondansetron hydrochloride | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Aug 14, 2026 | In Use | |
| 83980-0018-97 | 83980-0018 | Ondansetron hydrochloride | Ondansetron hydrochloride | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Aug 14, 2026 | In Use |
Found 12611 results — Export these results
Home